Bellerophon Therapeutics, Inc. announced that the first patient has been randomized into a Phase 2b study evaluating INOpulse in patients with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD). The first patient was treated at The Lung Research Center in Chesterfield, MO, by Neil A. Ettinger, M.D. The iNO-PF Phase 2b, randomized, double-blind, placebo-controlled clinical study will assess the safety and efficacy of pulsed, inhaled nitric oxide (iNO) versus placebo in patients with PH-ILD, including patients with idiopathic pulmonary fibrosis (PH-IPF). A total of 40 subjects will be enrolled in this clinical trial. The study design includes a 1-week run-in period, followed by an 8-week double-blinded treatment period. The primary endpoint of the study is the change in 6 Minute Walk Distance from baseline to week 8. The trial will include several additional endpoints, including the change in Right Ventricular Function.